Aug 6, 2026 06:30AM
May 27, 2026 06:00PM
Mar 17, 2026 07:30AM
Mar 17, 2026 07:30AM
Feb 18, 2026 07:30AM
Dec 18, 2025 07:30AM
Oct 30, 2025 07:30AM Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
Aug 7, 2025 07:30AM
Aug 4, 2025 04:30PM
Jul 31, 2025 04:30PM
Mar 26, 2025 07:30AM
Oct 15, 2024 08:30AM
Feb 29, 2024 07:30AM
Oct 16, 2023 07:30AM Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
Oct 10, 2023 04:45PM
Oct 6, 2022 06:12PM
Aug 11, 2022 07:30AM
Mar 29, 2022 07:36AM
Mar 24, 2022 07:30AM
Nov 8, 2021 10:00AM
Sep 23, 2021 07:30AM Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
May 14, 2021 07:30AM
Mar 1, 2021 07:04PM
Sep 21, 2020 05:01PM
Sep 21, 2020 05:01PM
Aug 25, 2020 07:33AM
Aug 25, 2020 07:30AM
Aug 25, 2020 07:30AM Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
Apr 17, 2020 07:30AM
Nov 25, 2019 04:15PM
Jun 26, 2019 08:30AM
Jun 25, 2019 08:30AM
Jun 18, 2019 05:00PM
Apr 4, 2019 08:45AM
Mar 14, 2019 08:30PM Knight Addresses Misleading and Self-Serving Plan Issued by Disgruntled Director
Jan 11, 2019 08:03AM
Jan 11, 2019 08:00AM
Nov 8, 2018 06:00AM
Nov 7, 2018 04:05PM
Sep 24, 2018 04:36PM
Aug 9, 2018 09:49AM
Aug 9, 2018 06:00AM Knight Therapeutics Reports Second Quarter 2018 Results
Jul 31, 2018 04:55PM
Jul 31, 2018 04:13PM
Jul 31, 2018 04:12PM
Jul 26, 2018 06:13PM
Jul 6, 2018 08:00AM
Mar 19, 2018 06:30AM
Mar 19, 2018 06:30AM Knight Announces Exclusive License Agreement with Ardelyx for Tenapanor
Feb 8, 2018 09:03AM

328,736 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All